{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:29:05Z","timestamp":1744298945453,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40261-021-01052-3","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T16:13:00Z","timestamp":1623341580000},"page":"639-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-5722","authenticated-orcid":false,"given":"Ashit","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Mackowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pegah","family":"Jafarinasabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Flach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Terminello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"1052_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10741-009-9135-0","volume":"14","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009;14:289\u201398. https:\/\/doi.org\/10.1007\/s10741-009-9135-0.","journal-title":"Heart Fail Rev"},{"issue":"6023","key":"1052_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023):1439\u201344.","journal-title":"Science"},{"issue":"9792","key":"1052_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","volume":"378","author":"JR Teerlink","year":"2011","unstructured":"Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378(9792):667\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(11)61219-1.","journal-title":"Lancet"},{"issue":"3","key":"1052_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5414\/CP202458","volume":"54","author":"R Palaparthy","year":"2016","unstructured":"Palaparthy R, Banfield C, Alvarez P, et al. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016;54(3):217\u201327. https:\/\/doi.org\/10.5414\/CP202458.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1052_CR5","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/ejhf.2015","volume":"22","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020;22(11):2160\u201371. https:\/\/doi.org\/10.1002\/ejhf.2015.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1052_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","volume":"8","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Hear Fail. 2020;8(4):329\u201340. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.001.","journal-title":"JACC Hear Fail."},{"issue":"7","key":"1052_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/children5070088","volume":"5","author":"B Das","year":"2018","unstructured":"Das B. Current state of pediatric heart failure. Children. 2018;5(7):88. https:\/\/doi.org\/10.3390\/children5070088.","journal-title":"Children"},{"issue":"6","key":"1052_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jpeds.2013.07.014","volume":"163","author":"V Klingmann","year":"2013","unstructured":"Klingmann V, Spomer N, Lerch C, et al. Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. J Pediatr. 2013;163(6):1728\u201333. https:\/\/doi.org\/10.1016\/j.jpeds.2013.07.014.","journal-title":"J Pediatr"},{"key":"1052_CR9","unstructured":"World Health Organization. Report of the informal expert meeting on dosage forms of medicines for children. 2008. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/application\/paediatric\/Dosage_form_reportDEC2008.pdf."},{"issue":"2","key":"1052_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1542\/peds.2013-3225","volume":"134","author":"V Ivanovska","year":"2014","unstructured":"Ivanovska V, Rademaker CMA, Van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134(2):361\u201372. https:\/\/doi.org\/10.1542\/peds.2013-3225.","journal-title":"Pediatrics"},{"issue":"4","key":"1052_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pedneo.2017.01.001","volume":"58","author":"D Masarone","year":"2017","unstructured":"Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: A practical guide to diagnosis and management. Pediatr Neonatol. 2017;58(4):303\u201312. https:\/\/doi.org\/10.1016\/j.pedneo.2017.01.001.","journal-title":"Pediatr Neonatol"},{"issue":"10062","key":"1052_CR12","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895\u2013903. https:\/\/doi.org\/10.1016\/S0140-6736(16)32049-9.","journal-title":"Lancet"},{"issue":"12","key":"1052_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, Mcmurray JJV, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. J Am Coll Cardiol. 2016;67(12):1444\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2016.01.031.","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01052-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T18:34:53Z","timestamp":1625078093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01052-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01052-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"28 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Amgen, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AT, MM, PJ, HZ, BT, AB, SD, and EL are employees and shareholders of Amgen, Inc. SF has no relevant funding or compensation to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified researchers may request data from Amgen clinical studies; complete details are available at http:\/\/www.amgen.com\/datasharing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AT, MM, SD, and EL participated in the conception and planning of the study; all authors participated in the design of the study. All authors participated in the acquisition, analysis, and interpretation of data. All authors critically revised and approved the final version of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"The study was conducted in accordance with ethical guidelines from the Declaration of Helsinki and Council for International Organizations of Medical Sciences, applicable Good Clinical Practice guidelines of the International Council for Harmonization, and applicable local laws and regulations. A Salus (Austin, TX, USA) institutional review board approved the research protocol and study-related documents.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study subjects provided written informed consent before enrollment in the study and could withdraw from the study at any time.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors would like to thank Yuan-Hon Kiang and Bhanu Bejgum from Process Development, Amgen Inc. for providing valuable information related to formulations.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}}]}}